BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

MultiCorp International, Inc. /XTend Medical (MCIC) Name Change and Symbol Change Finalized


8/28/2012 9:45:46 AM

SUN VALLEY, CA--(Marketwire - August 27, 2012) - MultiCorp International, Inc. /XTend Medical Corporation (PINKSHEETS: XMDC), has finalized the name/symbol change with FINRA and the company will begin trading under the symbol MCIC effective on August 28, 2012.

The company also announced that the CEO and President of the company have converted their holdings of common shares back into preferred shares, thus lowering the outstanding shares by 400 million.

The company released the following statement: "The Company has finalized the name change and symbol change only with FINRA and the new symbol, MCIC, will become effective tomorrow, August 28, 2012. As FINRA had changed their policies regarding the process to complete these steps, this action took longer than first perceived. This will better reflect our new direction for the company. In addition, Mr. Friedman and Mr. Lisenby decided to convert 400 million common shares back to 40 million preferred shares. This will lower the company's outstanding common shares by 400 million," stated Mr. Paul D. Lisenby, CEO of MultiCorp International, Inc. Mr. Lisenby further states, "The Company will continue to aggressively pursue acquisitions that have potential to grow revenues and profits for MultiCorp and their shareholders. If the acquisition targets meet the company's criteria of management and business sector for growth, then MultiCorp will move forward with our due diligence process and close these accordingly."

About MultiCorp International, Inc. /XTend Medical

MultiCorp International, Inc./ XTend Medical is a company that operates its core business in the medical field but also has several wholly owned subsidiaries such as Rivalz Sports Group, Inc. www.rivalzsports.com and JoyFull Genius, Inc., www.joyfullgenius.com. The company will continue to capitalize on growth sectors with solid business models and management that have the potential to grow exponentially and will have additional subsidiaries. For further information please contact them at info@multicorpinternational.com

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.


CONTACT
XTend Medical Corporation/MultiCorp International, Inc.
www.multicorpinternational.com
info@multicorpinternational.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->